Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - Implications for clinical practice

Andrologia

Volumn 38, Issue 1, 2006, Pages 1-12

  Yassin, A ^a,b,g   Saad, F ^b   Hoesl, C E ^c   Traish, A M ^d   Hammadeh, M ^e   Shabsigh, R ^f  

^a Segeberger Kliniken   (Germany)

^b GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF MUNICH   (Germany)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g NONE   (Germany)

Author keywords

adrenoceptor; adrenoceptor blockers; Ageing; Benign prostatic hyperplasia erectile dysfunction

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; PHOSPHODIESTERASE INHIBITOR;

AGING; ASTHENIA; BLADDER STONE; CLINICAL PRACTICE; CLINICAL TRIAL; CORPUS CAVERNOSUM; CORRELATION ANALYSIS; DATA ANALYSIS; DETRUSOR MUSCLE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SELECTIVITY; EJACULATION DISORDER; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; HUMAN; HYPOTENSION; INFORMATION RETRIEVAL; KIDNEY FAILURE; MEDICAL DOCUMENTATION; MEDLINE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PENIS ERECTION; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PUBLICATION; RECEPTOR AFFINITY; RETROGRADE EJACULATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL FUNCTION; SMOOTH MUSCLE CONTRACTILITY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION; CHEMISTRY; DRUG COMBINATION; IMPOTENCE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DYSFUNCTION; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-ANTAGONISTS; AGING; DRUG THERAPY, COMBINATION; HUMANS; IMPOTENCE; MALE; MUSCLE, SMOOTH, VASCULAR; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; UROLOGIC DISEASES;

EID: 33644981152     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2006.00709.x     Document Type: Review

References (110)

1. Akduman B Crawford ED 2001 Terazosin, doxazosin, and prazosin: current clinical experience Urology 58 Suppl 1 49 54
2. Andersson KE Wagner G 1995 Physiology of penile erection Physiol Rev 75 191 236
3. Arrighi HM Metter EJ Guess HA Fozzard JL 1991 Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging Urology 38 Suppl 4 8
4. Berry SJ Coffey DS Walsh PC Ewing LL 1984 The development of human benign prostatic hyperplasia with age J Urol 132 474 479
5. Bing W Chang S Hypolite JA DiSanto ME Zderic SA Rolf L Wein AJ Chacko S 2003 Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase Am J Physiol Renal Physiol 285 F990 F997
6. Bloch W Klotz T Loch C Schmidt G Engelmann U Addicks K 1997 Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide Prostate 33 1 8
7. Blum MD Bahnson RR Porter TN Carter MF 1985 Effect of local alpha-adrenergic blockade on human penile erection J Urol 134 479 481
8. Boyle P Robertson C Mazzeta C Keech M Hobbs R Fourcade R Kiemeney L Lee C and the UrEpik study group 2003 The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik studyq10 Br J Urol 92 719 725
9. Braun M Wassmer G Klotz T Reifenrath B Mathers M Engelmann U 2000 Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey' Int J Impot Res 12 305 311
10. Braun MH Sommer F Haupt G Mathers MJ Reifenrath B Engelmann UH 2003 Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'aging male' symptoms? Results of the 'Cologne Male Survey' Eur Urol 44 588 594
11. Brindley GS 1983 Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence Br J Psychiat 143 332 337
12. Buzelin JM Fonteyne E Kontturi M Wijjes WPJ Khan A for the European Tamsulosin Study Group 1997 Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia) Br J Urol 80 597 605
13. Bylund DB Eikenberg DC Hieble JP Langer SZ Lefkowitz RJ Minneman KP Molinoff PB Ruffolo RR Jr. Trendelenburg U 1994 International Union of Pharmacology nomenclature of adrenoceptors Pharmacol Rev 46 121 136
14. Byrnes CA Morton AS Liss CL Lippert MC Gillenwater JY 1995 Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar Clin Ther 17 956 969
15. Carbone DJ Jr. Hodges S 2003 Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life Int J Impot Res 15 299 306
16. Chang S Hypolite JA Zderic SA Wein AJ Chacko S DiSanto ME 2002 Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction J Urol 167 2636 2644
17. Chapple CR Wyndaele JJ Nordling J Boeminghaus F Ypma AF Abrams P 1996 Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group Eur Urol 29 155 167
18. Chapple CR Lorenz J Mortensen R Pauthner H Reis MO Schulman CC van der Putten-Slob I 2005a Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study Eur Urol 4 Suppl 25 32
19. Chapple CR Al-Shukri SH Gattegno B Holmes S Martinez-Sagarra JM Scarpa RM van Vierssen Trip OB Vik V van der Putten-Slob I 2005b Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study Eur Urol 4 Suppl 33 44
20. Chitaley K Wingard CJ Clinton Webb R Branam H Stopper VS Lewis RW Mills TM 2001 Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway Nat Med 7 119 122
21. Chitaley K Webb RC Mills TM 2003 The ups and downs of rho-kinase and penile erection: upstream regulators and downstream substrates of rho-kinase and their potential role in the erectile response Int J Impot Res 15 105 109
22. Chou EC Capello SA Levin RM Longhurst PA 2003 Excitatory alpha1-adrenergic receptors predominate over inhibitory beta-receptors in rabbit dorsal detrusor J Urol 170 2503 2507
23. De Rose AF Carmignani G Corbu C Giglio M Traverso P Naselli A Belgrano E Catuogno C Fontana D Maver A Mirone V Muzzonigro G Di Trapani D Bonini F 2002a Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia Urol Int 68 95 98
24. De Rose AF Giglio M Traverso P Lantieri P Carmignani G 2002b Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy Int J Impot Res 14 50 53
25. Diederichs W Stief CG Lue TF Tanagho EA 1990 Norepinephrine involvement in penile detumescence J Urol 143 1264 1266
26. Dunn CJ Matheson A Faulds DM 2002 Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms Drugs Aging 19 135 161
27. Fitzpatrick JM Desgrandchamps F 2005 The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia BJU Int 95 575 579
28. Ford AP Daniels DV Chang DJ Gever JR Jasper JR Lesnick JD Clarke DE 1997 Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification Br J Pharmacol 121 1127 1135
29. Frankel SJ Donovan JL Peters TI Abrams P Dabhoiwala NF Osawa D Tong Long Lin A 1998 Sexual dysfunction in men with lower urinary tract symptoms J Clin Epidemiol 51 677 685
30. Girman CJ Jacobsen SJ Tsukamoto T Richard F Garraway WM Sagnier PP Guess HA Rhodes T Boyle P Lieber MM 1998 Health-related quality of life associated with lower urinary tract symptoms in four countries Urology 51 428 436
31. Gisleskog PO Hermann D Hammarlund-Udenaes M Karlsson MO 1998 A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride Clin Pharmacol Ther 64 636 647
32. Goepel M Krege S Price DT Michelotti GA Schwinn DA Michel MC 1999 Characterization of alpha- adrenoceptor subtypes in the corpus cavernosum of patients undergoing sex change surgery J Urol 162 1793 1799
33. Grimm RH Jr. Grandits GA Prineas RJ McDonald RH Lewis CE Flack JM Yunis C Svendsen K Liebson PR Elmer PJ 1997 Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) Hypertension 29 8 14
34. Guay DR 2004 Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia Am J Geriatr Pharmacother 2 14 23
35. Hatano A Takahashi H Tamaki M Komeyama T Koizumi T Takeda M 1994 Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery Br J Pharmacol 113 723 728
36. Hedlund H Andersson KE Mattiasson A 1984 Pre- and postjunctional adreno- and muscarinic receptor functions in the isolated human corpus spongiosum urethrae J Auton Pharmacol 4 241 249
37. Hellstrom WJG 2005 Impact of BPH medical treatment on sexual function. Symposium; urogenital health: a new paradigm for male integrated core In: Paper Presented at Congress of the European Association of Urology; March 17 Istanbul, Turkey
38. Hernandez Fernandez C Moncada Iribarren I Jara Rascon J Castano Gonzalez I Moralejo Garate M 2004 Treatment with Doxazosin in 3347 patients with lower urinary tract symptoms. Impact on sexual function. The impros study Actas Urol Esp 28 290 297
39. Hoesl CE Woll EM Burkart M Altwein JE 2005 Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS) Eur Urol 47 511 517
40. Höfner K Claes H De Reijkec TM Folkestad B Speakman MJ for the European Tamsulosin Study Group 1999 Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 335 341
41. Hopps CV Mulhall JP 2003 Assessment of the impact of sildenafil citrate on LUTS in men with ED J Urol 169 Suppl 1401
42. Jacobsen SJ Jacobson DJ Girman CJ Roberts RO Rhodes T Guess HA Lieber MM 1997 Natural history of prostatism: risk factors for acute urinary retention J Urol 158 481 487
43. James S Chapple CR Phillips MI Greengrass PM Davey MJ Turner-Warwick RT Milroy EJ Burnstock G 1989 Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate J Urol 142 438 444
44. Jeong MS Lee JG 2000 The role of spinal and peripheral alpha1- and alpha2-adrenoceptors on bladder activity induced by bladder distension in anaesthetized rat BJU Int 85 925 931
45. Kaplan SA Reis RB Kohn IJ Shabsigh R Te AE 1998 Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction Urology 52 739 743
46. Kassabian VS 2003 Sexual function in patients treated for benign prostatic hyperplasia Lancet 361 60 62
47. Khan MA Dashwood MR Thompson CS Auld J Morgan RJ Mikhailidis DP 1999 Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance World J Urol 17 290 295
48. Kirby RS Andersen M Gratzke P Dahlstrand C Hoye K 2001 A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia BJU Int 87 192 200
49. Kirby RS O'Leary MP Carson C 2005 Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction BJU Int 95 103 109
50. Kloner RA Jackson G Emmick JT Mitchell MI Bedding A Warner MR Pereira A 2004 Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men J Urol 172 1935 1940
51. Klotz T Bloch W Loch C Engelmann U Addicks K 1997 Pattern of distribution of constitutive isoforms of NO synthase in the normal prostate and obstructive prostatic hyperplasia Urologe A 36 318 322
52. Lepor H 1998 Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 51 892 900
53. Lepor H Shapiro E 1984 Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia J Urol 132 1226 1229
54. Lepor H Williford WO Barry MJ Brawer MK Dixon CM Gormley G Haakenson C Machi M Narayan P Padley RJ 1996 The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group N Engl J Med 335 533 539
55. Lukacs B Leplege A Thibault P Jardin A 1996 Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results Urology 48 731 740
56. Lunenfeld B Saad F Hoesl CE 2005 ISA and ISSAM recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale Aging Male 8 59 74
57. Lytton B 1983 Interracial incidence of benign prostatic hypertrophy In Benign Prostatic Hyperthropy Hinman F ed Springer-Verlag New York pp 22
58. MacFarlane GJ Botto H Sagnier P-P Teillac P Richard F Boyle P 1996 The relationship between sexual life and urinary condition in the French community J Clin Epidemiol 10 1771 1776
59. Marshall I Burt RP Chapple CR 1995 Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype Br J Pharmacol 115 781 786
60. McConnell JD 1996 Guidelines for diagnosis and management of benign prostatic hyperplasia In Textbook of Benign Prostatic Hyperplasia Kirby R McConnell J Fitzpatrick J Roehrborn C Boyle P eds Isis Medical Media Ltd Oxford, UK pp 507 526
61. Mendes FR Hamamura M Queiroz DB Porto CS Avellar MC 2004 Effects of androgen manipulation on alpha1-adrenoceptor subtypes in the rat seminal vesicle Life Sci 75 1449 1463
62. Michel MC Flannery MT Narayan P 2001 Worldwide experience with alfuzosin and tamsulosin Urology 58 508 516
63. Michelotti GA Schwinn DA 2004 Mechanistic insights into the role of alpha1adrenergic receptors in lower urinary tract symptoms Curr Urol Rep 5 258 266
64. Misra KP Joglekar SJ Mukherjee S Nanivadekar AS 1998 Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group J Assoc Physicians India 46q11 Suppl 1 30 40
65. van Moorselaar RJ Hartung R Emberton M Harving N Matzkin H Elhilali M Alcaraz A Vallancien G ALF-ONE Study Group 2005 Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction BJU Int 95 603 608
66. Narayan P Lepor H 2001 Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia Urology 57 466 470
67. Nickel JC Fradet Y Boake RC Pommerville PJ Perreault JP Afridi SK Elhilali MM 1996 Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study CMAJ 155 1251 1259
68. Nicolosi A Glasser DB Moreira ED Villa M Erectile Dysfunction Epidemiology Cross National Study Group 2003 Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study Int J Impot Res 15 253 257
69. Nordling J 2005 Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia BJU Int 95 1006 1012
70. Norman RW Nickel JC Fish D Pickett SN 1994 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms Br J Urol 74 542 550
71. Perlberg S Caine M 1982 Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability Urology 20 524 527
72. Ponholzer A Temml C Obermayr R Madersbacher S 2004 Association between lower urinary tract symptoms and erectile dysfunction Urology 64 772 776
73. Price D 2001 Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists Eur Urol 40 Suppl 4 5 11
74. Reilly CM Stopper VS Mills TM 1997 Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum J Androl 18 26 31
75. Roehrborn CG Schwinn DA 2004 Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia J Urol 171 1029 1035
76. Roehrborn CG Oesterling JE Auerbach S Kaplan SA Lloyd LK Milam DE Padley RJ 1996 The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group Urology 47 159 168
77. Rohner TJ Hannigan JD Sanford EJ 1978 Altered in vitro adrenergic responses of dog detrusor muscle after chronic bladder outlet obstruction Urology 11 357 361
78. Rosen R Altwein J Boyle RS Kirby B Lukacs B Meuleman E O'Leary MP Puppo P Robertson C Guiliano F 2003 Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 637 649
79. Rosen RC Seidman SN Menza MA Shabsigh R Roose SP Tseng LJ Orazem J Siegel RL 2004 Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms Int J Impot Res 16 334 340
80. Saenz de Tejada I 2002 Molecular mechanisms for the regulation of penile smooth muscle contractility Int J Impot Res 14 Suppl 1 S6 S10
81. Saenz de Tejada I Goldstein I Krane RJ 1988 Local control of penile erection nerves, smooth muscle, and endothelium Urol Clin N Am 15 9 15
82. Sagnier P-P MacFarlane G Teillac P Botto H Richard F Boyle P 1995 Impact of symptoms of prostatism on level of bother and quality of life of men in the French Community J Urol 153 669 673
83. Sairam K Kulinskaya E McNicholas TA Boustead GB Hanbury DC 2002 Sildenafil influences lower urinary tract symptoms BJU Int 90 836 839
84. Sanchez-Cruz JJ Carbrera-Leon A Martin-Morales A Fernandez A Burgos R Rejas J 2003 Male erectile dysfunction and health-related quality of life Eur Urol 44 245 253
85. Schulman CC 2003 Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment Urology 62 24 33
86. Schulman CC Cortvriend J Jonas U Lock TM Vaage S Speakman MJ 1999 Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group Eur Urol 36 609 620
87. Schwinn DA 2000 Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms BJU Int 86 Suppl 2 11 20
88. Schwinn DA Michelotti GA 2000 Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression BJU Int 85 Suppl 2 6 11
89. Seo KK Lee MY Lim SW Kim SC 1999 Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin J Korean Med Sci 14 69 74
90. Shabsigh R 2004 Therapy of ED: PDE-5 inhibitors Endocrine 23 135 141
91. Somogyi GT Tanowitz M de Groat WC 1995 Prejunctional facilitatory alpha 1-adrenoceptors in the rat urinary bladder Br J Pharmacol 114 1710 1716
92. Tarcan T Azadzoi KM Siroky MB Goldstein I Krane RJ 1998 Age-related erectile and voiding dysfunction: the role of arterial insufficiency Br J Urol 82 Suppl 1 26 33
93. Tenover JL Pagano GA Morton AS Liss CL Byrnes CA 1997 Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group Clin Ther 19 243 258
94. Terai A Ichioka K Matsui Y Yoshimura K 2004 Association of lower urinary tract symptoms with erectile dysfunction in Japanese men Urology 64 132 136
95. Thompson CS Khan MA Dashwood MR Mumtaz FH Mikhailidis DP Morgan RJ 2000 Altered cavernosal endothelin-B-receptor binding sites in the rabbit model of partial bladder outlet obstruction J Cardiovasc Pharmacol 36 Suppl 1 S260 S261
96. Traish AM Netsuwan N Daley J Padman-Nathan H Goldstein I Saenz de Tejada I 1995a A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine J Urol 153 222 227
97. Traish AM Gupta S Toselli P de Tejada IS Goldstein I Moreland RB 1995b Identification of alpha 1-adrenergic receptor subtypes in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells Receptor 5 145 157
98. Traish A Gupta S Gallant C Huang YH Goldstein I 1998 Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms Int J Impot Res 10 215 223
99. Traish AM Park K Dhir V Kim NN Moreland RB Goldstein I 1999a Effects of castration and androgen replacement on erectile function in a rabbit model Endocrinology 140 1861 1868
100. Traish AM Kim NN Goldstein I Moreland RB 1999b Alpha-adrenergic receptors in the penis: identification, characterization, and physiological function J Androl 20 671 682
101. Traish AM Kim NN Moreland RB Goldstein I 2000 Role of alpha adrenergic receptors in erectile function Int J Impot Res 12 Suppl 1 48 63
102. Traish AM Munarriz R O'Connell L Choi S Kim SW Kim NN Huang YH Goldstein I 2003 Effects of medical or surgical castration on erectile function in an animal model J Androl 24 381 387
103. Uckert S Kuthe A Jonas U Stief CG 2001 Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2484 2490
104. Untergasser G Madersbacher S Berger P 2005 Benign prostatic hyperplasia: age-related tissue- remodeling Exp Gerontol 40 121 128
105. Vaidyanathan S Soni BM Singh G Sett P Krishnan KR 1998 Prolonged penile erection association with terazosin in a cervical spinal cord injury patient Spinal Cord 36 805
106. Vallancien G Emberton M Harving N van Moorselaar RJ Alf-One Study Group 2003 Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms J Urol 169 2257 2261
107. Wagner G Fugl-Meyer KS Fugl-Meyer AR 2000 Impact of erectile dysfunction on quality of life: patient and partner perspectives Int J Impot Res 12 Suppl 4 S144 S146
108. Yassin A Diede HE 2003 Combination therapy: alpha 1-adreno blockade and tadalafil in BPH population Int J Impot Res 15 Suppl 6 PS2 PS5
109. Ying J Yao D Jiang Y Ren X Xu M 2004 The positive effect of sildenafil on LUTS from BPH while treating ED Zhonghua Nan Ke Xue 10 681 683
110. Zorgniotti AW Lefleur RS 1985 Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence J Urol 133 39 41